Bone Biologics (NASDAQ:BBLG) Issues Quarterly Earnings Results

Bone Biologics (NASDAQ:BBLG) announced its quarterly earnings data on Friday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04), FiscalAI reports.

Bone Biologics Stock Down 2.9%

BBLG traded down $0.02 during trading on Friday, hitting $0.66. The company had a trading volume of 167,161 shares, compared to its average volume of 827,889. The company has a market capitalization of $1.19 million, a PE ratio of -0.29 and a beta of 0.92. Bone Biologics has a one year low of $0.62 and a one year high of $4.13. The firm’s 50-day moving average price is $1.18 and its 200 day moving average price is $1.25.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.